公开(公告)号：WO9965515A3

公开(公告)日：2000-03-09

申请号：PCT/US9913567

申请日：1999-06-15

Applicant: ARCH DEV CORP ,  BETH ISRAEL HOSPITAL ,  DANA FARBER CANCER INST INC ,  WEICHSELBAUM RALPH R ,  SUKHATME VIKAS P ,  KUFE DONALD W

Inventor： WEICHSELBAUM RALPH R ,  SUKHATME VIKAS P ,  KUFE DONALD W

IPC: C12N15/09 ,  A61K38/00 ,  A61K38/20 ,  A61K38/36 ,  A61K38/39 ,  A61K38/46 ,  A61K38/48 ,  A61K45/00 ,  A61K48/00 ,  A61P9/00 ,  A61P35/00 ,  A61P43/00 ,  A61K38/19

CPC classification number: A61K38/484 ,  A61K38/208 ,  A61K38/363 ,  A61K38/39 ,  A61K48/00 ,  A61K2300/00

Abstract: The present invention relates generally to the fields of angiogenesis and cancer therapy. More particularly, it concerns the use of anti-angiogenic factors in cancer therapy. The present invention demonstrates that angiostatin or endostatin can sensitize a cell to radiation therapy. Methods and compositions for inhibiting growth, sensitizing a cell to radiotherapy and treating cancer growth by first inhibiting angiogenesis and then employing radiotherapy are described.

Abstract translation: 本发明一般涉及血管发生和癌症治疗的领域。 更具体地说，它涉及抗癌血管生成因子在癌症治疗中的应用。 本发明证明血管抑素或内皮抑素可使细胞对放射治疗敏感。 描述了抑制生长的方法和组合物，通过首先抑制血管发生然后使用放射治疗使细胞对放射治疗敏感和治疗癌症生长。

公开(公告)号：WO9423030A3

公开(公告)日：1994-11-10

申请号：PCT/US9402611

申请日：1994-03-10

Applicant: ARCH DEV CORP

Inventor： SUKHATME VIKAS P

IPC: A61K38/00 ,  C07K14/47 ,  C07K14/475 ,  C07K16/18 ,  C12N15/12 ,  C12P21/08 ,  A61K37/02 ,  C07K13/00 ,  C12N15/62 ,  C12P21/02 ,  C12Q1/68 ,  G01N33/532

CPC classification number: C07K14/475 ,  A61K38/00 ,  C07K14/4702 ,  C07K16/18 ,  C07K2319/00 ,  C07K2319/09 ,  C07K2319/61 ,  C07K2319/71 ,  C07K2319/75 ,  C07K2319/81

Abstract: Disclosed are DNA sequences encoding novel DNA binding proteins implicated in regulation of early stages of cell growth. Illustratively provided are human and mouse origin DNA sequences encoding early growth regularoty ('Egr') proteins which include 'zinc finger' regions of the type involved in DNA binding. Also disclosed is a detailed analysis of the structure and function of the early growth regulatory protein, Egr-1, delineating independent and modular activation, repression, DNA-binding, and nuclear localization activities. Also disclosed are immunological methods and materials for detection of Egr proteins and hybridization methods and materials for detection and quantification of Egr protein related nucleic acids.

公开(公告)号：CA2335038A1

公开(公告)日：1999-12-23

申请号：CA2335038

申请日：1999-06-15

Applicant: BETH ISRAEL HOSPITAL ,  DANA FARBER CANCER INST INC ,  ARCH DEV CORP

Inventor： WEICHSELBAUM RALPH R ,  KUFE DONALD W ,  SUKHATME VIKAS P

IPC: C12N15/09 ,  A61K38/00 ,  A61K38/20 ,  A61K38/36 ,  A61K38/39 ,  A61K38/46 ,  A61K38/48 ,  A61K45/00 ,  A61K48/00 ,  A61P9/00 ,  A61P35/00 ,  A61P43/00 ,  A61K38/19

Abstract: The present invention relates generally to the fields of angiogenesis and cancer therapy. More particularly, it concerns the use of anti-angiogenic factors in cancer therapy. The present invention demonstrates that angiostat in or endostatin can sensitize a cell to radiation therapy. Methods and compositions for inhibiting growth, sensitizing a cell to radiotherapy and treating cancer growth by first inhibiting angiogenesis and then employing radiotherapy are described.

公开(公告)号：CA2098849C

公开(公告)日：2007-07-10

申请号：CA2098849

申请日：1991-12-19

Applicant: ARCH DEV CORP

Inventor： WEICHSELBAUM RALPH R ,  HALLAHAN DENNIS E ,  SUKHATME VIKAS P ,  KUFE DONALD W

IPC: C12N15/85 ,  A61K31/70 ,  A61K41/00 ,  A61K48/00 ,  A61K51/00 ,  A61P9/08 ,  A61P9/10 ,  A61P35/00 ,  C07K14/52 ,  C07K14/525 ,  C12N5/10 ,  C12N15/09 ,  C12N15/63 ,  C12N15/67

Abstract: This invention relates to genetic constructs which comprise an enhancer-promoter region which is responsive to radiation, and at least one structural gene whose expression is controlled by the enhancer-promoter. This invention also relates to methods of destroying, altering, or inactivating cells in target tissue by delivering the genetic constructs to the cells of the tissues and inducing expressing of the structural gene or genes in the construct by exposing the tissues to ionizing radiation. This invention is useful for treating patients with cancer, clotting disorders, myocardial infarction, and other diseases for which target tissues can be identified and for which gene expression of the construct within the target tissues can alleviate the disease or disorder.

公开(公告)号：DK0563278T3

公开(公告)日：2000-08-21

申请号：DK92903431

申请日：1991-12-19

Applicant: DANA FARBER CANCER INST INC ,  ARCH DEV CORP THE UNIVERSITY O

Inventor： WEICHSELBAUM RALPH R ,  SUKHATME VIKAS P ,  KUFE DONALD W ,  HALLAHAN DENNIS E

IPC: A61K41/00 ,  A61K48/00 ,  A61K51/00 ,  A61P9/08 ,  A61P9/10 ,  A61P35/00 ,  C07K14/52 ,  C07K14/525 ,  C12N15/09 ,  C12N15/63 ,  C12N15/67 ,  C12N15/85 ,  A01N43/04 ,  A61K43/00 ,  C07H15/12 ,  C12N15/62 ,  C12Q1/68

Abstract: This invention relates to genetic constructs which comprise an enhancer-promoter region which is responsive to radiation, and at least one structural gene whose expression is controlled by the enhancer-promoter. This invention also relates to methods of destroying, altering, or inactivating cells in target tissue by delivering the genetic constructs to the cells of the tissues and inducing expression of the structural gene or genes in the construct by exposing the tissues to ionizing radiation. This invention is useful for treating patients with cancer, clotting disorders, myocardial infarction, and other diseases for which target tissues can be identified and for which gene expression of the construct within the target tissues can alleviate the disease or disorder.

公开(公告)号：AU686112B2

公开(公告)日：1998-02-05

申请号：AU4850993

申请日：1993-09-08

Applicant: ARCH DEV CORP ,  DANA FARBER CANCER INST INC

Inventor： WEICHSELBAUM RALPH R ,  HALLAHAN DENNIS E ,  SUKHATME VIKAS P ,  KUFE DONALD W

IPC: C12N15/09 ,  A61K31/70 ,  A61K38/00 ,  A61K41/00 ,  A61K48/00 ,  A61K51/00 ,  A61P9/08 ,  A61P9/10 ,  A61P35/00 ,  C07H21/04 ,  C07K14/52 ,  C07K14/525 ,  C07K14/82 ,  C12N5/10 ,  C12N15/63 ,  C12N15/67 ,  C12N15/85 ,  G03G15/20 ,  C12N15/62

Abstract: The present invention provides a DNA molecule comprising a radiation responsive enhancer-promoter operatively linked to an encoding region that encodes at least one polypeptide. An encoding region can comprise a single encoding sequence for a polypeptide or two or more encoding sequences encoding DNA binding, activation or repression domains of a transcription factor. Processes for regulating polypeptide expression and inhibiting tumor growth using such DNA molecules are also provided.

公开(公告)号：CA2098849A1

公开(公告)日：1992-06-21

申请号：CA2098849

申请日：1991-12-19

Applicant: ARCH DEV CORP ,  DANA FARBER CANCER INST INC

Inventor： WEICHSELBAUM RALPH R ,  HALLAHAN DENNIS E ,  SUKHATME VIKAS P ,  KUFE DONALD W

IPC: A61K41/00 ,  A61K48/00 ,  A61K51/00 ,  A61P9/08 ,  A61P9/10 ,  A61P35/00 ,  C07K14/52 ,  C07K14/525 ,  C12N15/09 ,  C12N15/63 ,  C12N15/67 ,  C12N15/85 ,  A61K31/70

Abstract: V This is invention relates to genetic constructs which comprise an enhancer-promoter region which is responsive to radiation, and at least one structural gene whose expression is controlled by the enhancer-promoter. This invention also relates to methods of destroying, altering, or inactivating cells in target tissue by delivering the genetic constructs to the cells of the tissues and inducing expressing of the structural gene or genes in the construct by exposing the tissues to ionizing radiation. This invention is useful for treating patients with cancer, clotting disorders, myocardial infarction, and other diseases for which target tissues can be identified and for which gene expression of the construct within the target tissues can alleviate the disease or disorder.

公开(公告)号：AU762615B2

公开(公告)日：2003-07-03

申请号：AU4570799

申请日：1999-06-15

Applicant: ARCH DEV CORP ,  BETH ISRAEL HOSPITAL ,  DANA FARBER CANCER INST INC

Inventor： WEICHSELBAUM RALPH R ,  SUKHATME VIKAS P ,  KUFE DONALD W

IPC: C12N15/09 ,  A61K38/00 ,  A61K38/20 ,  A61K38/36 ,  A61K38/39 ,  A61K38/46 ,  A61K38/48 ,  A61K45/00 ,  A61K48/00 ,  A61P9/00 ,  A61P35/00 ,  A61P43/00 ,  A61K38/19

Abstract: The present invention relates generally to the fields of angiogenesis and cancer therapy. More particularly, it concerns the use of anti-angiogenic factors in cancer therapy. The present invention demonstrates that angiostatin or endostatin can sensitize a cell to radiation therapy. Methods and compositions for inhibiting growth, sensitizing a cell to radiotherapy and treating cancer growth by first inhibiting angiogenesis and then employing radiotherapy are described.

公开(公告)号：AU657111B2

公开(公告)日：1995-03-02

申请号：AU9170291

申请日：1991-12-19

Applicant: ARCH DEV CORP ,  DANA FARBER CANCER INST INC

Inventor： WEICHSELBAUM RALPH R ,  HALLAHAN DENNIS E ,  SUKHATME VIKAS P ,  KUFE DONALD W

IPC: A61K41/00 ,  A61K48/00 ,  A61K51/00 ,  A61P9/08 ,  A61P9/10 ,  A61P35/00 ,  C07K14/52 ,  C07K14/525 ,  C12N15/09 ,  C12N15/63 ,  C12N15/67 ,  C12N15/85 ,  A61K43/00 ,  C12Q1/68

Abstract: This invention relates to genetic constructs which comprise an enhancer-promoter region which is responsive to radiation, and at least one structural gene whose expression is controlled by the enhancer-promoter. This invention also relates to methods of destroying, altering, or inactivating cells in target tissue by delivering the genetic constructs to the cells of the tissues and inducing expression of the structural gene or genes in the construct by exposing the tissues to ionizing radiation. This invention is useful for treating patients with cancer, clotting disorders, myocardial infarction, and other diseases for which target tissues can be identified and for which gene expression of the construct within the target tissues can alleviate the disease or disorder.

公开(公告)号：AU6402694A

公开(公告)日：1994-10-24

申请号：AU6402694

申请日：1994-03-10

Applicant: ARCH DEV CORP

Inventor： SUKHATME VIKAS P

IPC: A61K38/00 ,  C07K14/47 ,  C07K14/475 ,  C07K16/18 ,  C12N15/12 ,  C12P21/08 ,  C07K13/00 ,  C12N15/62 ,  C12P21/02 ,  G01N33/532 ,  C12Q1/68 ,  A61K37/02

Abstract: Disclosed are DNA sequences encoding novel DNA binding proteins implicated in regulation of early stages of cell growth. Illustratively provided are human and mouse origin DNA sequences encoding early growth regulatory ("Egr") proteins which include "zinc finger" regions of the type involved in DNA binding. Also disclosed is a detailed analysis of the structure and function of the early growth regulatory protein, Egr-1, delineating independent and modular activation, repression, DNA-binding, and nuclear localization activities. Also disclosed are immunological methods and materials for detection of Egr proteins and hybridization methods and materials for detection and quantification of Egr protein related nucleic acids.